 While in
the Pharm.D. program at the University of Kentucky, Dr. Schondelmeyer
served as the national president of the Student American Pharmaceutical
Association. He has remained active in APhA and is currently chair of the
APhA’s Economic, Social, and Administrative Sciences Section. He was one
of the founding members of the International Society of Pharmaceutical
Outcomes Research and he belongs to many other professional societies and
associations.
Dr.
Schondelmeyer’s research interests encompass health care economics and
public policy as they relate to pharmacists and pharmaceuticals. Specific
areas of interests include: affordability of medicines for elderly,
indigent, and other populations; financing and design of drug therapy
benefit programs; monitoring pharmaceutical economic trend indicators
related to pharmacists, pharmacies, wholesalers, manufacturers, drug
products, consumers, insurers, and pharmaceutical benefit managers; and
characterization of the economic life cycle of drug therapy markets and
the nature of competition among drug products.
He has
conducted policy analysis in many areas such as payment for prescription
drugs under Medicaid, Medicare, managed care and other third party
programs. He was appointed to the Prescription Drug Payment Review
Commission that served in an oversight and advisory capacity to Congress
for the quickly repealed Medicare outpatient drug program. He has
conducted research projects for a variety of sponsors including: the
Health Care Financing Administration, the U.S. General Accounting office
(GAO), the Congressional Office of Technology Assessment (OTA), the U.S.
Senate Special Committee on Aging, the Food and Drug Administration (FDA),
the pharmaceutical industry, and pharmacy associations. He has also worked
with a number of states to develop drug assistance programs for the
elderly and to address other pharmaceutical policy issues including:
Kentucky, Ohio, Missouri, Pennsylvania, Indiana, Vermont, Iowa, Minnesota,
California, and Maine.
Many
countries have called upon the expertise of Dr. Schondelmeyer and the
PRIME Institute including: Canada, Mexico, England, Spain, France, South
Africa, South Korea, Taiwan, Thailand, Singapore, Venezuela, Uruguay,
Ecuador, and Argentina. These consultation projects and activities are
typically with the Minister of Health in the country and have encompassed
objectives such as assuring affordable access to quality pharmaceuticals,
designing systems for drug product and pharmaceutical care delivery,
monitoring and evaluating the role of prescription drugs in a national
health insurance program, economic and policy role of generic
pharmaceuticals in a developing country, and many other topics related to
the role of pharmaceuticals in society.
He has
published many papers and his research has been widely quoted in the
scientific, policy, and public press. His research papers have often been
referenced in government reports and proceedings including: Congressional
Budget Office, Congressional Research Service, Office of Technology
Assessment, General Accounting Office, the Congressional Record, and
various committee reports and proceedings. Quotes and citations have
included: Time, U.S. News & World Report, Fortune, Forbes, The Wall
Street Journal, The New York Times, The Pink Sheet, American Pharmacy,
American Druggist, Health Affairs, JAMA, NEJM, American Medical
Association News, and Pharmaceutical Executive.
|
Back
to